Perrigo urges adoption of non-organ-specific alcohol/analgesic warning.
This article was originally published in The Tan Sheet
Executive Summary
NON-ORGAN-SPECIFIC ANALGESIC/ALCOHOL WARNING URGED BY PERRIGO in Jan. 27 comments to FDA on the agency's proposed rule calling for alcohol warnings on analgesic products. The private label manufacturer suggests that instead of FDA's proposed warnings, which are product and organ specific, the agency adopt the warning it previously recommended be voluntarily used by the OTC industry, which directs the consumer to consult a physician if he/she "generally consumes three or more alcohol-alcohol drinks per day." Allegan, Mich.-based Perrigo uses the voluntary warning on all of its acetaminophen products.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning